New cancer vaccine approaches

Drugs of Today

Volumn 40, Issue 11, 2004, Pages 913-929

  Kaplan, Johanne M ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOVECTIN 7; BCG VACCINE; CANCER VACCINE; GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HLA B7 ANTIGEN; LEUVECTIN; MELACINE; PLASMID DNA; POLYSORBATE 80; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; SQUALENE; TRASTUZUMAB; TUMOR VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; CANCER; CANCER IMMUNOTHERAPY; CELL DAMAGE; DRUG EFFICACY; HUMAN; REVIEW; SIDE EFFECT; TARGET CELL; TREATMENT PLANNING; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; TREATMENT FAILURE;

EID: 11844251962     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.11.872580     Document Type: Review

References (128)

1. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002, 3: 991-8.
2. Mihm, M.C., Jr., Clemente, C.J., Cascinelli, N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996, 74: 43-7.
3. Lipponen, P.K., Ekselinen, M.J., Jauhiainen, K., Harju, E., Terho, R. Tumor infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer 1992, 29A: 69-75.
4. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998, 58: 3491-4.
5. Dudley, M.E., Wunderlich, J.R., Robbins, P.F. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298: 850-4.
6. Igney, F.H., Krammer, P.H. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 2002, 71: 907-20.
7. Marincola, F.M., Wang, E., Herlyn, M., Seliger, B., Ferrone, S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003, 24: 335-42.
8. Mitchell, M.S. Cancer vaccines, a critical review - Part I. Curr Opin Invest Drugs 2002, 3: 140-9.
9. Vaisnampayan, U., Abrams, J., Darrah, D., Jones, V., Mitchell, M.S. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res 2002, 8: 3696-701.
10. Vilella, R., Benitez, D., Mila, J. et al. Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine. Int J Cancer 2003, 106: 626-31.
11. Berd, D. Autologous, hapten-modified vaccine as a treatment for human cancers. Clin Exp Dermatol 2002, 27: 597-601.
12. Armstrong, T.D., Jaffee, E.M. Cytokine modified tumor vaccines. Surg Oncol Clinics N Am 2002, 11: 681-96.
13. Dranoff, G. GM-CSF-secreting melanoma vaccines. Oncogene 2003, 22: 3188-92.
14. Ward, S., Casey, D., Labarthe, M.C. et al. Immunotherapeutic potential of whole tumor cells. Cancer Immunol Immunother 2002, 51: 351-7.
15. Ribas, A., Butterfield, L.H., Glaspy, J.A., Economou, J.S. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003, 21: 2415-32.
16. Sosman, J.A., Sondak, V.K. Melacine: An allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines 2003, 2: 353-68.
17. Mathe, G., Halle-Pannenko, O., Bourut, C. BCG in cancer immunotherapy: Results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy. Natl Cancer Inst Monogr 1973, 39: 107-13.
18. Kaushik, A. Leuvectin Vical Inc. Curr Opin Investig Drugs 2001, 2: 976-81.
19. Bergen, M., Chen, R., Gonzalez, R. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7R) in patients with metastatic melanoma. Expert Opin Biol Ther 2003, 3: 377-84.
20. Tong, T., Song, W., Crystal, R.G. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 2001, 61: 7530-5.
21. Crittenden, M., Gough, M., Harrington, K., Olivier, K., Thompson, J., Vile, R.G. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res 2003, 63: 5505-12.
22. Bramson, J.L., Bodner, C.A., Graham, R.W. Activation of host anti-tumoral responses by cationic/lipid DMA complexes. Cancer Gene Ther 2000, 7: 353-9.
23. Lanuti, M., Rudginsky, S., Force, S.D. et al. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in intraperitoneal tumor models. Cancer Res 2000, 60: 2955-63.
24. Rudginsky, A., Siders, W., Ingram, L., Marshall, J., Scheule, R., Kaplan, J. Antitumor activity of cationic lipid complexed with immunostimulatory DNA. Molec Ther 2001, 4: 347-55.
25. Siders, W.M., Vergillis, K., Johnson, C., Scheule, R.K., Kaplan, J.M. Tumor treatment with complexes of cationic lipid and noncoding plasmid DNA results in the induction of cytotoxic T cells and systemic tumor elimination. Molec Ther 2002, 6: 519-27.
26. Nestle, F.O., Alijagic, S., Gilliet, M. et al. Vaccination of melanoma patients with peptide or tumor lysate pulsed dendritic cells. Nat Med 1998, 4: 328-32.
27. Geiger, J.D., Hutchinson, R.J., Hohenkirk, L.F. et al. Vaccination of pediatric solid tumor patients with tumor lysate pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001, 61: 8513-9.
28. Chang, A.E., Redman B.G., Whitfield, J.R. et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002, 8: 1021-32.
29. Wolfers, J., Lozier, A., Raposo, G. et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001, 7: 297-303.
30. Albert, M.L., Sauter, B., Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392: 86-9.
31. Lambert, L.A., Gibson, G.R., Maloney, M., Barth, R.J., Jr. Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole tumor cell antigens. J Immunother 2001, 24: 232-6.
32. Boczkowski, D., Nair, S.K., Snyder, D., Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996, 184: 465-72.
33. Su, Z., Dannull, J., Heiser, A. et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003, 63: 2127-33.
34. Gong, J., Chen, D., Kashiwaba, M., Kufe, D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med 1997, 3: 558-61.
35. Lespagnard, L., Mettens, P., Verheyden, A.M. et al. Dendritic cells used with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer 1998, 76: 250-8.
36. Siders, W.M., Vergilis, K.L., Johnson, C., Shields, J., Kaplan, J.M. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Molec Ther 2003, 7: 498-505.
37. Kugler, A., Stuhler, G., Waiden, P. et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med 2000, 6: 332-6.
38. Phan, V., Errington, F., Cneong, S.C. A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nature Med 2003, 9: 1215-9.
39. Kugler, A., Stuhler, G., Waiden, P. et al. Retraction: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med 2003, 9: 1221.
40. Marten, A., Renoth, S., Heinicke, T. et al. Allogeneic dendritic cells fused with tumor cells: Prectinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Human Gen Ther 2003, 14: 483-94.
41. Srivastava, P.K., Udono, H., Blachere, N.E., Li, Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994, 39: 93-8.
42. Tamura, Y., Peng, P., Liu, K., Daou, M., Srivastava, P. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997, 2778: 117-20.
43. Basu, S., Binder, R.J., Ramalingam, T., Srivastava, P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14: 303-13.
44. Parmiani, G., Rivoltini, L., Belli, F. et al. Vaccination of metastatic melanoma patients with the autologous heat shock protein peptide complex-96 (HSPPC-96; Oncophage) which contains melanoma peptides, results in specific T cell response and clinical response. Meeting of the American Society for Clinical Oncology 2002, Abstr. 49.
45. Assikis, V.J., Daliani, D., Pagliaro, L. et al. Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSP-PC-96) for patients with metastatic renal cell carcinoma (mRCC). Meeting of the American Society for Clinical Oncology 2003, Abstr. 1552.
46. Van der Bruggen, P., Traversari, C., Chomez, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254: 1643-7.
47. Rosenberg, S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997, 18: 175-82.
48. Cheever, M.A., Disis, M.L., Bernhard, H. et al. Immunity to oncogenic proteins. Immunol Rev 1995, 145: 33-59.
49. Blake, J., Johnston, J.V., Hellstrom, K.E., Marguardt, H., Chen, L. Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC Class I-restricted cytolytic lymphocytes. J Exp Med 1996, 184: 121-30.
50. Hiemstra, H., Drijfhout, J.W., Roep, B.O. Antigen arrays in T cell immunology. Curr Opin Immunol 2000, 12: 80-4.
51. Lawendowski, C.A., Giurleo, G.M., Huang, Y.Y. et al. Solid Phase Epitope Recovery: A high throughput method for antigen identification and epitope optimization. J Immunol 2002, 169: 2414-21.
52. + T cells. J Exp Med 1999, 189: 757-66.
53. Wang, R.F., Wang, X., Atwood, A.C., Topalian, S.L., Rosenberg, S.A. Cloning genes encoding MHC Class II-restricted antigens: Mutated CDC27 as a tumor antigen. Science 1999, 284: 1351-4.
54. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 2000, 165: 1153-9.
55. Miles, D.W. Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting. Breast Cancer Res 2001, 3: 380-4.
56. Grillo-Lopex, A.J., White, C.A., Varns, C. et al. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999, 26: 66-73.
57. Sahin, U., Tureci, O., Pfreundschuh, M. Serological identification of human tumor antigens. Curr Opin Immunol 1997, 9: 709-16.
58. Old, L.J., Chen, Y.T. New paths in human cancer serology. J Exp Med 1998, 187: 1163-7.
59. Huang, Y., Franklin, J., Gifford, K., Roberts, B.L., Nicolette, C.A. A high throughput proteogenomics method to identify antibody targets associated with malignant disease. Clin Immunol 2004, 111: 202-9.
60. Velculescu, V.E., Zhang, L., Vogelstein, B., Kinzler, K.W. Serial analysis of gene expression. Science 1995, 270: 484-7.
61. Buteau, C., Markovic, S.N., Celis, E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc 2002, 77: 339-49.
62. Weber, J. Melanoma peptide vaccines: From preclinical background to clinical trials. Curr Oncol Reports 2000, 2: 38-47.
63. Parmiani, G., Castelli, C., Dalerba, P. et al. Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going? J Natl Cancer Inst 2002, 94: 805-18.
64. Wang, R.F. Enhancing antitumor immune responses: Intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol Rev 2002, 188: 65-80.
65. Thurner, B., Haendle, I., Roder, C. et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999, 190: 1669-78.
66. Slingluff, C.L., Jr., Yamshchikov, G., Neese, P. et al. Phase I trial of a melanoma vaccine with gp100 280-288 peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes. Clin Cancer Res 2001, 7: 3012-24.
67. Casares, N., Lasarte, J.J., Lopez Diaz de Ceiro, A., et al. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol 2001, 31: 1780-9.
68. + T cells by a single peptide with dual MHC Class I and Class II specificities: A new strategy for vaccine design. Cancer Res 2002, 62: 3630-5.
69. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J. et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 1999, 163: 1690-5.
70. Miconnet, I., Koenig, S., Speiser, D. et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 2002, 168: 1212-8.
71. Mattner, F., Fleitmann, J.K., Lingnau, K. et al. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: Induction of potent and long-lasting T cell responses against cancer antigens. Cancer Res 2002, 62: 1477-80.
72. Pullarkat, V., Lee, P.P., Scotland, R. et al. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res 2003, 9: 1301-12.
73. Fong, L., Hou, Y., Rivas, A. et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001, 98: 8809-14.
74. Valmori, D., Levy, F., Miconnet, I. et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue. J Immunol 2000, 164: 1125-31.
75. Bonnet, M.C., Tartaglia, J., Verdier, F. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 2000, 74: 11-25.
76. Thomson, S.A., Sherritt, M.A., Medveczky, J. et al. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J Immunol 1998, 160: 1717-23.
77. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998, 4: 321-7.
78. Zaremba, S., Barzaga, E., Zhu, M., Soares, N., Tsang, K.Y., Schlom, J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997, 57: 4570-7.
79. Zhu, D., Stevenson, F.K. DNA gene fusion vaccines against cancer. Curr Opin Molec Ther 2002, 4: 41-8.
80. Wolff, J.A., Ludtke, J.J., Ascadi, G., Williams, P., Jani, A. Long term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992, 1: 363-9.
81. McAllister, D.V., Allen, M.G., Prausnitz, M.R. Microfabricated microneedles for gene and drug delivery. Ann Rev Biomed Eng 2000, 2: 289-313.
82. + T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003, 21: 4036-42.
83. Trezise, A.E. In vivo DNA electrotransfer. Cell Biol 2002, 21: 869-77.
84. + T cell responses and delays tumor growth in a syngeneic mouse melanoma model. Cancer Res 2002, 62: 5489-94.
85. Klencke, B., Matijevic, M., Urban, R.G. et al. Encapsulated plasmid DNA treatment for human papilloma virus 16-associated anal dysplasia: A phase I study of ZYC101. Clin Cancer Res 2002, 8: 1028-37.
86. Denis-Mize, K.S., Dupuis, M., MacKicahn, M.L. et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 2000, 7: 2105-12.
87. Okamoto, T., Kaneda, Y., Yuzuki, D., Huang, S.K.S., Chi, D.D.J., Hoon, D.S.B. Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine. Gene Ther 1997, 4: 969-76.
88. Maloy, K.J., Erdmann, I., Basch, V. et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001, 98: 3299-303.
89. Densmore, C.L., Orson, P.M., Xu, B. et al. Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol Ther 2000, 1: 180-8.
90. Xiang, R., Primus, F.J., Ruehlmann, J.M. et al. A dual function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell mediated protective immunity against colon cancer in carcinoembryonic antigen transgenic mice. J Immunol 2001, 167: 4560-5.
91. Xiang, R., Lode, H.N., Chao, T.H. et al. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci USA 2000, 97: 5492-7.
92. You, Z., Huang, X., Hester, J., Toh, H.C., Chen S.Y. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 2001, 61: 3704-11.
93. Hung, C.P., Hsu, K.P., Cheng, W.F. et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 2001, 61: 1080-8.
94. Michel, N., Osen, W., Gissman, L., Schumacher, T.N.M., Zentgraf, H., Muller, M. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 2002, 294: 47-59.
95. Hung, C.P., He, L., Juang, J., Lin, T.J., Ling, M., Wu, T.C. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 2002, 76: 2676-82.
96. Chen, C.H., Ji, H., Suh, K.W., Choti, M.A., Pardoll, D.M., Wu, T.C. Gene gun mediated DNA vaccination induces antitumor immunity against human papilloma virus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 1999, 6: 1972-81.
97. Haupt, K., Roggendorf, M., Mann, K. The potential of DNA vaccination against tumor-associated antigens for anti-tumor therapy. Exp Biol Med 2002, 227: 227-37.
98. Sasaki, S., Amara, R.R., Oran, A.E., Smith, J.M., Robinson, H.L. Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nature Biotech 2001, 19: 43-7.
99. Leitner, W.W., Hwang, L.N., DeVeer, M.J. et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nature Med 2003, 9: 33-9.
100. Gilbert, S.C., Schneider, J., Hannan, C.M. et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malarial model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002, 20: 1039-45.
101. Allen, T.M., Vogel, T.U., Fuller, D.H. et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus ankara boost regimen. J Immunol 2000, 164: 4968-78.
102. Meng, W.S., Butterfield, L.H., Ribas, A. et al. Alpha-fetoprotein- specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001, 61: 8782-6.
103. Humrich, J., Jenne, L. Viral vectors for dendritic cell-based immunotherapy. Curr Top Microbiol Immunol 2003, 276: 241-59.
104. Kirk, C.J., Mule, J.J. Gene-modified dendritic cells for use in tumor vaccines. Human Gene Ther 2000, 11: 796-806.
105. Jenne, L., Hauser, C., Arright, J.F., Saurat, J.H., Hugin, A.W. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: Abortive infection but reduced APC function. Gene Ther 2000, 7: 1575-83.
106. Kaplan, J.M., Yu, Q., Piraino, S.T. et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector encoding endogenous tumor-associated antigens. J Immunol 1999, 163: 699-707.
107. Aarts, W.M., Schlom, J., Hodge, J.W. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002, 62: 5770-7.
108. + T cells: Implications for an efficient vaccine strategy. Gene Ther 2003, 10: 243-50.
109. Oertli, D., Marti, W.R., Zajac, P. et al. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules. Human Gene Ther 2002, 13: 569-75.
110. Okada, N., Masunaga, Y., Okada, Y. et al. Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus. Cancer Gene Ther 2003, 10: 421-31.
111. Tillman, B.W., de Gruijl, T.D., Luykx-de Bakker, S.A. et al. Maturation of dendritic cells accompanies high efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol 1999, 162: 6378-83.
112. Xia, D.J., Zhang, W.P., Zheng, S. et al. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Gene Ther 2002, 9: 592-601.
113. Wiethe, C., Dittmar, K., Doan, T., Lindenmaier, W., Tindle, R. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol 2003, 170: 2912-22.
114. Hodge, J.W., Grosenbach, D.W., Schlom, J. Vector-based delivery of tumor-associated antigens and T cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. Cancer Detect Prev 2002, 26: 275-91.
115. Ullenhag, G.J., Frodin, J.F., Mosolits, S. et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response. Clin Cancer Res 2003, 9: 2447-56.
116. Kwak, H., Horig, H., Kaufman, H.L. Pox-viruses as vectors for cancer immunotherapy. Curr Opin Drug Disc Dev 2003, 6: 161-8.
117. Gorelik, L., Flavell, R.A. Immune-mediated eradication of tumors though the blockade of transforming growth factor beta signaling in T cells. Nature Med 2001, 7: 1118-22.
118. Kobie, J.J., Wu, R.S., Kurt, R.A. et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003, 63: 1860-4.
119. Egen, J.G., Kuhns, M.S., Allison, J.P. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nature Immunol 2002, 3: 611-8.
120. van Elsas, A., Hurwitz, A.A., Allison, J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/ macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190: 355-66.
121. Hurwitz, A.A., Foster, B.A., Kwon, E.D. et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000, 60: 2444-8.
122. Espenschied, J., Lamont, J., Longmate, J. et al. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 2003, 170: 3401-7.
123. Hodi, F.S., Mihm, M.C., Soiffer, R.J. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003, 100: 4712-7.
124. Phan, G.Q., Yang, J.C., Sherry, R.M. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003, 100: 8372-7.
125. + regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor beta. Cancer Res 2002, 62: 5267-72.
126. Ahlers, J.D., Belyakov, I.M., Terabe, M. et al. A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. PNAS 2002, 99: 13020-5.
127. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001, 194: 823-32.
128. Moingeon, P. Cancer vaccines. Vaccine 2001, 19: 1305-26.